Selected Publications

Cillo AR, Cardello C, Shan F, Karapetyan L, Kunning S, Sander C, Rush E, Karunamurthy A, Massa RC, Rohatgi A, Workman CJ, Kirkwood JM, Bruno TC, Vignali DAA.: Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8(+) T cells to promote antitumor immunity. Cell 187(16): 4373-4388, Aug 2024.

Eads JR, Graham N, Gibson MK, Rajdev L, Chakravarthy AB, Khullar OV, Lin SH, Wistuba II, Agarwal R, Blazar M, Mehta DR, Al Baghdadi T, Jin N, Massa RC, Hamilton SR, Staley CA, Wong TZ, O'Dwyer PJ.: A phase II/III study of peri-operative nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of the neoadjuvant pathologic complete response (pCR) rate (ECOG-ACRIN EA2174). J Clin Oncol, American Society of Clinical Oncology Annual Meeting, Chicago, IL. 42: (suppl 16; abstr 4000), Jun 2024 Notes: "Poster Presentation"

Karapetya L, Karunamurthy A, Cillo A, Wang S, Massa RC, Rohatgi A, Deitrick C, Najjar YG, Davar D, Luke JJ, Sander C, Rose A, Rush E, Joy M, Kunning S, Bao R, Wang H, Bruno TC, Vignali DD, Kirkwood JM: Randomized phase II evaluation of nivolumab (nivo), or relatlimab (rela), or combined nivo-rela lead-in followed by nivo-rela as first line therapy for patients (pts) with advanced melanoma (mel) J Clin Oncol, American Society of Clinical Oncology Annual Meeting, Chicago, IL. 42: (suppl 16; abstr 9525), Jun 2024 Notes: "Poster Presentation"

Tuteja S, Cayabyab MA, Hoffecker G, Varughese L, Wittner V, Ndayishmiye JDD, Wang X, Harr M, Santani A, Hakonarson H, Massa RC, Damjanov N, Reddy NJ, Oyer RA, Teitelbaum UR: Implementing DPYD/UGT1A1 testing to prevent treatment related adverse events (TRAE) in patients with gastrointestinal (GI) cancer: Results of a pragmatic implementation trial J Clin Oncol, American Society of Clinical Oncology Annual Meeting, Chicago, IL. 42: (suppl 16; abstr 10599), Jun 2024 Notes: "Poster Presentation"

Eads J, Chapin W, Massa R: Defining the Role of Neoadjuvant Therapy for Gastroesophageal Cancers. Advances in Oncology. Platanias LC (eds.). 4, 2024.

Karasic TB, Brown TJ, Schneider C, Teitelbaum UR, Reiss KA, Mitchell TC, Massa RC, O'Hara MH, DiCicco L, Garcia-Marcano L, Amaravadi RK, O'Dwyer PJ.: Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer. Oncologist 27(9): 716-e689, Sep 2022.

Reiss KA, Mick R, Teitelbaum U, O'Hara M, Schneider C, Massa R, Karasic T, Tondon R, Onyiah C, Gosselin MK, Donze A, Domchek SM, Vonderheide RH.: Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial. Lancet Oncol 23(8): 1009-1020. Aug 2022.

Brown TJ, Massa RC.: Challenges in the Management of Patients With HER2-Amplified Colorectal Cancer. JCO Oncol Pract 18(8): 555-556, Aug 2022.

Varughese LA, Bhupathiraju M, Hoffecker G, Terek S, Harr M, Hakonarson H, Cambareri C, Marini J, Landgraf J, Chen J, Kanter G, Lau-Min KS, Massa RC, Damjanov N, Reddy NJ, Oyer RA, Teitelbaum UR, Tuteja S.: Implementing Pharmacogenetic Testing in Gastrointestinal Cancers (IMPACT-GI): Study Protocol for a Pragmatic Implementation Trial for Establishing DPYD and UGT1A1 Screening to Guide Chemotherapy Dosing. Front Oncol 12: 859846, Jul 2022.

Chapin WJ, Massa RC, Eads JR.: Evolving standards of care for neoadjuvant and adjuvant therapy in esophageal, gastroesophageal junction, and gastric cancer. Clin Adv Hematol Oncol 19(12): 784-793, Dec 2021.